Pulmonary arterial hypertension is a clinical and pathophysiological syndrome of elevated pulmonary vascular resistance and pulmonary artery pressure due to left heart disease, lung disease and chronic hypoxia, etc. There are the following five classes of new targeted drugs for the treatment of pulmonary arterial hypertension. 1. Endothelin receptor antagonists: such as bosentan, anlisentan, macitentan, etc. Common adverse effects include peripheral edema and anemia; 2. phosphodiesterase type 5 inhibitors (PDE5 inhibitors): such as sildenafil, tadalafil, vardenafil, common adverse reactions include headache, flushing, myalgia, etc; 3. soluble guanylate cyclase agonists: leucovorin, common adverse reactions are gastrointestinal symptoms, including bloating, nausea, vomiting, etc., as well as low blood pressure and anemia; 4. prostacyclin analogs: iprostenol, iloprost, traprostinil, common adverse reactions include headache, flushing, hypotension, and also pain at the infusion site; 5. prostacyclin receptor agonists: Slepagel, common adverse reactions include headache, diarrhea, nausea and vomiting, jaw pain. There are numerous classifications and causes of pulmonary hypertension. Medications should be used under the guidance of a physician and in strict compliance with medical advice.